



Express Mail Label No. _____

Dated: _____

Docket No.: 03818/0202874-US0
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Nedjeljko Kujundzic et al.

Application No.: 10/534,628

Confirmation No.: N/A

Filed: May 10, 2005

Art Unit: N/A

For: SUBSTITUTED 9A-N-(N'-
(SULFONYL)PHENYLCARBAMOYL)
DERIVATIVES OF 9-DEOXO-9-DIHYDRO-
9A-AZA-9A-HOMOERITHOMYCIN A AND
5-O-DESOSAMINYL-9-DEOXO-9-
DIHYDRO-9A-AZA-9A-
HOMOERITHRONOLIDE A

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark

Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: October 20, 2005

Respectfully submitted,

By  *Erin Brown*
(53,970)
Adda C. Gogoris
Registration No.: 29,714
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 527-7701 (Fax)
Attorneys/Agents For Applicant



PTO/SB/08a/b (07-05)

ed for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/534,628
Filing Date	May 10, 2005
First Named Inventor	Nedjeljko Kujundzic
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	03818/0202874-US0

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-4,328, 334	05-04-1982	G. Kobrehel et al.	
	AB*	US-4,474, 768	10-02-1984	G. M. Bright et al.	
	AC*	US-4,492, 688,	01-08-1985	Bright G. M.	
	AD*	US-6,852,702	02-08-2005	Kujundzic , et al.	
	AE*	US-6,872,707	03-29-2005	Marusic-Istuk , et al.	
	AF*	US 5,629,296	05-13-1997	Kujundzic et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	EP 0316 128	07-17-1981	G. M. Bright et al.		
	BB	FR-2,473, 525	03-03-1993	G. S. Ambrieres		
	BC	BE 892,397	01-07-1982	Kobrehel et al.		
	BD	WO 2004/043984	05-27-2004	KUJUNDZIC, Nedjeljko et al.		✓
	BE	WO 2004/052904	06-24-2004	KUJUNDZIC, Nedjeljko et al.		✓
	BF	WO 97/35590	10-02-1997	Chris E. Platt		✓
	BG	EP 0657 464	10-30-1996	KUJUNDZIC, Nedjeljko et al.		✓
	BH	EP 0132 944	12-30-1986	G. M. Bright		✓

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	McGuire [Antibiotics and Chemotherapy, vol II, no. 6 (6/1952) 281-283]	
	CB	P. Kurath et al., Experientia 27/4 (1971) 362	
	CC	S. E Djokic et al., Tetrahedron Letters, no. 17, 4/1967: 1645-1647	
	CD	R. S. Egan et al., J. Org. Chem. No. 17, vol. 39 (8/1974) 2492-2494	
	CE	P. Lugar et al., Journal of Crystal and Molecular Structure, vol. 9, no. 6 (12/1979) 329-338	
	CF	Journal of Antibiotics, vol. 46, no. 8 (1/1993) 1239-1245 (G. Kobrehel et al.)	
	CG	Azalides: synthesis and antibacterial activity of novel 9a-N-(N'-substituted carbamoyl and thiocarbamoyl) derivatives of 9-deoxo-9a-aza-9a-homoerythromycin A; N Kujundzic et al., PLIVA, Research Institute, Eur J. Med Chem (1995) 30, 455-462	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--